AstraZeneca collaborates with Roche Diagnostics to advance personalised healthcare across therapeutic areas
Wednesday, 26 September 2012
AstraZeneca today announced it has entered into a collaboration agreement with Roche Diagnostics (the Diagnostics division of Roche) to develop companion diagnostics for selected products in development at AstraZeneca and MedImmune. The collaboration will span all of AstraZeneca’s therapy areas -- gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease.
The collaboration creates an efficient framework between AstraZeneca and several Roche Diagnostics Business Units (Roche Molecular Diagnostics, Roche Tissue Diagnostics, Roche Applied Science, Roche Professional Diagnostics), and will focus on the development of specialised in vitro diagnostic (IVD) products, research use only assays (RUO) and/or similar assays.
With companion diagnostics for most late-stage investigational medicines and patient stratification integrated into more than three quarters of medicines in development, AstraZeneca is committed to finding the biomarkers and diagnostics to ensure the company delivers effective medicines that target a responsive patient population.
Bob Holland, Vice President and Head, Personalised Healthcare and Biomarkers, AstraZeneca said: “We believe that personalised medicine is vital to the future of effective healthcare. We are pleased to be collaborating with Roche Diagnostics, who are a world leader in this field, in order to accelerate the advancement of companion diagnostics across disease areas to enhance clinical trial recruitment and bring targeted therapies to patients more quickly.”
Personalised healthcare is at the centre of AstraZeneca’s approach to drug discovery and development and this collaboration is part of the company’s strategy to seek external partners to identify, validate and manufacture diagnostics to regulatory standards.
“We recognise that early collaboration with the right partners to share capabilities and expertise, and match treatments to companion diagnostics is critical to progressing personalised medicine. AstraZeneca is working hand-in-hand with industry and academic institutions to develop and validate registration-ready biomarkers and companion diagnostics and advance patient care,” said Holland.
– ENDS –
NOTES TO EDITORS
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
+44 20 7604 8221